Introduction

Targeted radionuclide therapy (TRT) with alpha- and betaemitters
provides a precise cancer treatment approach that
improves outcomes while limiting systemic toxicity. The
development of new radiopharmaceuticals relies on robust in
vitro and in vivo assays to assess target specificity,
pharmacokinetics, biodistribution, resistance mechanisms, and
therapeutic index.